Prof. Kunyu Yang 杨坤禹
Chief Physician, Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy, chemotherapy, molecular targeted therapy, and CyberKnife treatment for nasopharyngeal, head and neck, and lung cancers.
Dr. Yang holds a medical degree and serves as Director of the Oncology Center at Union Hospital. Training includes fellowships at Saarland University Hospital (2003), MD Anderson Cancer Center (2008), and Memorial Sloan Kettering Cancer Center (2014). Research focuses on radiation pneumonitis and nasopharyngeal cancer radiosensitivity, with publications in journals such as New England Journal of Medicine and Lancet Oncology.
Professional roles
- Vice Chair, Nasopharyngeal Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Head and Neck Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Radiotherapy Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Chair, Radiotherapy Physician Branch, Hubei Medical Doctor Association
Name order: in Chinese the family name comes first (Yang Kunyu). Papers usually list the name as Kunyu Yang or Yang K.
Selected publications
194 papers on PubMed matched by name and affiliation; 54 as first or senior author since 2016. Most recent first- or senior-author papers:
- Biochim Biophys Acta Rev Cancer, 2026 (senior author): Co-opted immune homeostatic restraint in cancer: Mechanisms of immunosuppression and implications for immunotherapy resistance. PubMed 42971368
- Clin Cancer Res, 2026 (senior author): Response-Adapted Surgery after Neoadjuvant Immunochemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH): A Single-Arm Phase II Trial. PubMed 42717678
- Cancer, 2026 (senior author): Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O(6)-methylguanine-DNA methyltransferase glioblastoma: A single-arm, phase 2 study. PubMed 42339996
- J Extracell Vesicles, 2026 (senior author): Chemoradiotherapy-Integrated Tumor Cell-Derived Microparticles Mediate Tumor Eradication in Malignant Pleural Effusion. PubMed 41944389
- Front Bioeng Biotechnol, 2026 (senior author): Correction: Radiated tumor cell-derived microparticles effectively kill stem-like tumor cells by increasing reactive oxygen species. PubMed 41852782
- Mol Clin Oncol, 2025 (senior author): Extended progression-free survival after combination treatment with anlotinib and S-1 in refractory advanced esophageal cancer: A case report. PubMed 40529101
- Theranostics, 2025 (senior author): Boosting mRNA cancer vaccine efficacy via targeting Irg1 on macrophages in lymph nodes. PubMed 40521193
- Cancer Res, 2025 (senior author): Macrophage-Derived Itaconate Suppresses Dendritic Cell Function to Promote Acquired Resistance to Anti-PD-1 Immunotherapy. PubMed 40036156
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion